Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: biotech/medical – Page 325

“My hunch is the ancestor of all animals could regenerate its heart after an injury, and then that’s been repeatedly lost in different types of animals,” said Dr. James Gagnon. “I would like to understand why. Why would you lose this great feature that allows you to regenerate your heart after an injury?”

Can the heart physiology of zebrafish help treat human heart conditions? This is what a recent study published in Biology Open hopes to address as a team of researchers from the University of Utah compared the fish species of zebrafish and medaka since the former possesses heart regeneration capabilities while the latter does not. This study holds the potential to help researchers better understand the physiological processes responsible for fixing heart tissue after damage from a heart attack or other ailment that could lead to more advanced human treatments.

“We thought by comparing these two fish that have similar heart morphology and live in similar habitats, we could have a better chance of actually finding what the main differences are,” said Dr. Clayton Carey, a postdoctoral fellow at the University of Utah and lead author of the study.

For the study, the researchers injured the heart of each fish species that mirrored human heart attacks then removed the hearts after between 3 to 14 days after the procedure to examine how each was repaired since the injury. While 95 percent of the fish initially survived the procedure, they perished shortly afterwards. The team focused on analyzing immune cell behavior with the team noting that zebrafish possess certain types of muscle cells that weren’t present in medaka. In the end, the researchers concluded that evolutionary divergence was the likely reason why zebrafish possess heart regeneration capabilities whereas medaka do not.

Continue reading “Understanding heart regeneration and the potential for human applications” | >

Cannabinol (CBN) is a chemical found in cannabis that exhibits milder psychoactive properties than most cannabis chemicals, though research pertaining to its medical applications remains limited. Now, a team of researchers led by The Salk Institute for Biological Studies have published a study in Redox Biology that addresses the potential for CBN to serve as a method for neurological disorders, including traumatic brain injuries, Parkinson’s disease, and Alzheimer’s disease.

For the study, the researchers produced four CBN analogs that exhibited greater neuroprotective capabilities compared to the traditional CBN molecule and tested them on Drosophila fruit flies. In the end, the researchers discovered these CBN analogs possessed neuroprotective capabilities that surpassed traditional CBN molecules, including the treating of traumatic brain injuries. While not tested during this study, these CBN analogs could be used to also treat a myriad of neurological disorders, including Parkinson’s disease, Alzheimer’s disease, and Huntington’s disease.

“Our findings help demonstrate the therapeutic potential of CBN, as well as the scientific opportunity we have to replicate and refine its drug-like properties,” said Dr. Pamela Maher, who is a research professor in the Cellular Neurobiology Laboratory at Salk and a co-author on the study. “Could we one day give this CBN analog to football players the day before a big game, or to car accident survivors as they arrive in the hospital? We’re excited to see how effective these compounds might be in protecting the brain from further damage.”

Read more | >

Mount Sinai researchers, in collaboration with scientists at The Rockefeller University, have uncovered a mechanism in the brain that allows cocaine and morphine to take over natural reward processing systems. Published online in Science on April 18, these findings shed new light on the neural underpinnings of drug addiction and could offer new mechanistic insights to inform basic research, clinical practice, and potential therapeutic solutions.

Read more | >

Although schizophrenia can be a very complex illness some new studies show that some major genetic factors could be the cause and then cured much easier through gene therapy.

Summary: Researchers leveraged cutting-edge technology to gain insights into schizophrenia’s neurodevelopmental origins. The researchers grew brain organoids from patients’ skin cells, finding persistent axonal disruptions in those with schizophrenia.

In another study, researchers zeroed in on a schizophrenia risk gene, CYFIP1, revealing its potential role in brain immune cells called microglia and their influence on synaptic pruning – a crucial process for brain health.

Read more | >

What’s the optimal way to dose a longevity drug like rapamycin? Nils Osmar looks at some different studies that provide a possible answer:

It’s worth noting that mTORC2 is not directly inhibited by rapamycin under most circumstances, but can be under some. Some studies have found that after prolonged use, rapamycin can also begin inhibiting mTORC2 (see study: Alternative rapamycin treatment regimens mitigate the impact of rapamycin on glucose homeostasis and the immune system).

So taking breaks from rapamycin may also be beneficial.

Could taking some time off undermine rapamycin’s anti-aging benefits? It’s hard to know for sure, because people are so long-lived there’s no way to test its effects on human aging directly. But in mice, at least, it’s been found that administering rapamycin for two weeks out of every four can still significantly extend lifespan (see study: Alternative rapamycin treatment regimens mitigate the impact of rapamycin on glucose homeostasis and the immune system).

Continue reading “Rapamycin and Longevity: A Few Thoughts On Dosing” | >

Using lasers and metal powder, Australian scientists have created a super strong, super lightweight new — but they got the idea for this sci fi-sounding creation from plants.

The challenge: Materials that are strong yet lightweight, such as carbon fiber and graphene, are used to make everything from medical implants to airships, and developing ones with ever greater “strength-to-weight ratios” is the goal of many material scientists.

In pursuit of that goal, some have turned to nature, looking for ways to replicate in metal the hollow lattice structures, like those in the Victoria water lily, that make some plants remarkably strong.

Read more | >

Summary: Researchers uncovered how certain brain cells enhance our ability to maintain and focus on short-term memories. Their study highlights a new type of neuron, dubbed PAC neurons, which coordinate the activity of memory-specific neurons without storing any information themselves.

These findings were derived from the brain activity recordings of epilepsy patients during memory tasks, providing novel insights into how working memory functions. Understanding these mechanisms may lead to improved treatments for disorders like Alzheimer’s and ADHD, where such cognitive functions are impaired.

Read more | >

As anyone with seasonal allergies knows, unseen airborne particles can really wreck a person’s day. Like the tree pollen that might be plaguing you this spring, small concentrations of trace elements in the air can have significant negative impacts on human health. However, unlike pollen counts and other allergy indices, which are carefully tracked and widely available, limited knowledge exists about the ambient concentrations of cancer-causing trace elements like lead and arsenic in urban areas of developing countries.

Read more | >

An innovative programmable tool for targeting nucleic acids has been created, utilizing a prokaryotic immune defense system—and it is not CRISPR-Cas. Russian Academy of Sciences researchers have successfully re-engineered prokaryotic Argonautes (pAgos) to utilize RNA guides for locating nucleic acid sequences. These systems have been modified to form a complex with effector nucleases.

The researchers employed a two-component system known as SPARDA (short prokaryotic Argonaute, DNase, and RNase-associated) to effectively identify DNA sequences with a notable level of sensitivity and induce collateral nuclease activity. SPARDA and other concise pAgos systems that encode diverse effectors have the potential to offer a novel programmable tool for the field of biotechnology.

The research article “DNA-targeting short Argonautes complex with effector proteins for collateral nuclease activity and bacterial population immunity” was published in Nature Microbiology.

Read more | >